Long-Term Clinical Data Reveals Pralsetinib Dramatically Extends Survival for Patients With Advanced RET Fusion Lung Cancer

Mass General Brigham study shows pralsetinib quadruples survival for RET-positive lung cancer patients, highlighting the power of targeted genetic therapy.

By: AXL Media

Published: Apr 2, 2026, 4:26 AM EDT

Source: Information for this report was sourced from Mass General Brigham.

A Paradigm Shift in Lung Cancer Survivability

The landscape of thoracic oncology has undergone a significant transformation with the release of long-term data regarding selective RET inhibitors. Historically, patients diagnosed with advanced RET fusion-positive non-small cell lung cancer faced a grim prognosis, with median survival rates typically stagnating between four and eleven months. However, the latest findings from the Mass General Brigham Cancer Institute show that pralsetinib, an FDA-approved targeted therapy, has extended that median survival to 44 months. This nearly fourfold increase in life expectancy marks a departure from traditional broad-spectrum treatments, moving toward a highly individualized approach that targets the specific genetic drivers of tumor growth.

The Crucial Role of Genetic Biomarker Testing

The success of pralsetinib underscores a growing mandate within the medical community for comprehensive genomic profiling at the point of diagnosis. Because the drug specifically inhibits the RET gene fusions that drive certain tumors, its efficacy is entirely dependent on identifying the correct patient population through early biomarker testing. Senior author Dr. Justin Gainor notes that these findings reinforce the necessity of screening all metastatic lung cancer patients for gene fusions. By identifying these specific molecular signatures early, clinicians can bypass less effective systemic treatments and move directly to targeted therapies that offer a significantly higher probability of a durable clinical response.

Clinical Efficacy Across Diverse Patient Profiles

The ARROW study, an open-label phase 1/2 trial, followed 281 patients to evaluate how pralsetinib performed across different treatment histories and disease progression stages. The results were remarkably consistent, showing an overall response rate of 78% in patients who had received no prior therapy and 63% in those who had previously undergone chemotherapy. Perhaps most significantly, the drug demonstrated a 73% response rate in patients where the cancer had already metastasized to the brain. This suggests that the therapy is capable of crossing the blood-brain barrier, providing a critical therapeutic option for one of the most challenging complications of advanced lung cancer.